Blend Therapeutics rebranded at “Tarveda Therapeutics” a few months ago to reflect the strategic change the company underwent in 2015. A prospective cancer drug was spun into a new startup as part of that undertaking, and today, that company—Placon Therapeutics—has … Continued
Alveo is pleased to announce that it has closed its Series B financing round. The round was led byPrelude Ventures. Also participating are Khosla Ventures, NanoDimension, and Fluxus Ventures.
For most asthma sufferers, today’s inhaler drugs are helpful at calming attacks. But for about 10 to 15% of patients who have severe asthma, they don’t help much. These are the patients whose cases who end up in emergency rooms … Continued
Emulate, Inc., today announced the official opening of its new headquarters and laboratories in Boston’s Seaport District, at 27 Drydock Avenue within The Innovation and Design Building. The new facility will be a workplace for the company’s 40 employees, with … Continued
ARMO BioSciences, Inc., a clinical-stage biotechnology company, today announced the successful completion of a $50 million Series C private financing. ARMO intends to use the proceeds from the financing to support the clinical development of its lead product candidate, AM0010 for … Continued
Pulse Therapeutics, a St. Louis-based medical device startup, has raised approximately $10 million from a group of investors led by Silicon Valley venture capital firm NanoDimension. Also participating in the deal were St. Louis-based FTL Capital and Cultivation Capital. Pulse … Continued
Tarveda Therapeutics, Inc., today announced the appointment of Leila Alland, M.D. to the position of Chief Medical Officer. Dr. Alland brings more than 15 years of pharmaceutical drug development experience with a focus on oncology including leadership roles in clinical … Continued
Tarveda Therapeutics, Inc., formerly Blend Therapeutics, today announced that it has secured $38 million in Series C financing co-led by new investor Novo A/S and existing investor New Enterprise Associates (NEA). The company also announced the change of its corporate … Continued
Twist Bioscience, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today announced the completion of a $61 million Series D private financing. Crossover participants in the round include ARCH Overage Fund, Merieux Developpement, Cormorant Asset Management LLC, … Continued